News >

Venetoclax Combo Reaches High CR Rate in Older AML Patients

Published: Wednesday, Dec 20, 2017

The most common all-grade treatment-emergent adverse events (TEAEs) were nausea (74%), hypokalemia (48%), fatigue (46%), diarrhea (46%), decreased appetite (41%), constipation (38%), febrile neutropenia (36%), hypomagnesemia (34%), and vomiting (33%).

The most common grade ≥3 TEAEs were febrile neutropenia (36%), hypokalemia (16%), pneumonia (15%), AML progression (13%), hypophosphatemia (13%), hypertension (11%), and sepsis (10%).
Weis A, Strickland SA, Roboz GJ, et al. Phase 1/2 study of venetoclax with low-dose cytarabine in treatment-naive, elderly patients with acute myeloid leukemia unfit for intensive chemotherapy: 1-year outcomes. Presented at: American Society of Hematology 59th Annual meeting; December 9-12, 2017; Atlanta, GA. Abstract 890.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x